David Harel, CytoReason CEO
Touting nine-figure deal package, Pfizer extends collaboration with AI partner
More than two years after Pfizer tied the knot with machine learning firm CytoReason in an AI-focused deal, the two companies have agreed to keep …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
